6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis-Reference-Cited by-同舟云学术

6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis

Published:2017-09-28 Issue:10 Volume:8 Page:1019-1024
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Tong Amy S. T.¹,Choi Peter J.¹,Blaser Adrian¹,Sutherland Hamish S.¹,Tsang Sophia K. Y.¹,Guillemont Jerome²,Motte Magali²,Cooper Christopher B.³,Andries Koen⁴,Van den Broeck Walter⁴,Franzblau Scott G.⁵,Upton Anna M.³,Denny William A.¹^ORCID,Palmer Brian D.¹,Conole Daniel¹

Affiliation:

1. Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand

2. Medicinal Chemistry Department (Infectious Diseases), Janssen Pharmaceuticals, Campus de Maigremont, BP315, 27106 Val de Reuil Cedex, France

3. Global Alliance for TB Drug Development, 40 Wall Street, New York, New York 10005, United States

4. Infectious Diseases BVBA, Janssen Pharmaceuticals, Beerse, Belgium

5. Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, United States

Funder

Irish Aid

Bill and Melinda Gates Foundation

United States Agency for International Development

Department for International Development

Directoraat-Generaal Internationale Samenwerking

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

http://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.7b00196

Reference21 articles.

1. Challenges Associated with Current and Future TB Treatment

2. Diarylquinolines target subunit c of mycobacterial ATP synthase

3. Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance

4. Global Alliance for TB. Phase 2a Published Results Show the Potential of a New TB Regimen with Novel Drugs Bedaquiline and Pretomanid (PA-824).http://www.tballiance.org/newscenter/view-brief.php?id=1114(published 29 January 2015).

5. Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N-Acyl phenothiazines as mycobacterial ATP synthase inhibitors: Rational design, synthesis and in vitro evaluation against drug sensitive, RR and MDR-TB;Bioorganic Chemistry;2024-10

2. Contribution of telacebec to novel drug regimens in a murine tuberculosis model;2024-06-27

3. New synergistic benzoquinone scaffolds as inhibitors of mycobacterial cytochrome bc1 complex to treat multi-drug resistant tuberculosis;European Journal of Medicinal Chemistry;2024-06

4. Identification of new anti-mycobacterial agents based on quinoline-isatin hybrids targeting enoyl acyl carrier protein reductase (InhA);Bioorganic Chemistry;2024-03

5. Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid;Journal of Medicinal Chemistry;2024-02-14